Cancer immunotherapy (English Wikipedia)

"Elotuzumab Package Insert" (PDF). Archived (PDF) from the original on 8 December 2015.
"Empliciti (elotuzumab) for Injection, for Intravenous Use. Full Prescribing Information" (PDF). Empliciti (elotuzumab) for US Healthcare Professionals. Princeton, New Jersey: Bristol-Myers Squibb Company. Archived from the original (PDF) on 8 December 2015.

books.google.com

Dissertation Abstracts International: Retrospective Index, Volumes I-XXIX. University Microfilms. 1970.

canada.ca

"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

cancer.gov

"Immunotherapy to Treat Cancer". National Cancer Institute. 24 September 2019. Retrieved 14 October 2023.
Pazdur R. "FDA approval for Ipilimumab". Archived from the original on 6 April 2015. Retrieved 7 November 2013.
"National Cancer Institute - Pembrolizumab Use in Cancer". 18 September 2014.

training.seer.cancer.gov

"Types of Biological Therapy". SEER Training Modules. National Cancer Institute. Retrieved 14 October 2023.

cancer.net

"What are Cancer Vaccines?". Cancer.Net. 30 September 2013. Retrieved 15 August 2021.

cancer.org

"Coriolus Versicolor". American Cancer Society. Archived from the original on 15 February 2006.

cancergenetics.com

"Cancer Genetics offers the FDA-approved DAKO PD-L1 IHC 22C3 pharmDx companion diagnostic test for KEYTRUDA®". 3 February 2016.

clinicaltrials.gov

Clinical trial number NCT01928394 for "A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov

curetoday.com

Cure today (April 2016). "Durvalumab continues to progress in treatment of advanced bladder cancer".

doi.org

Kodach LL, Peppelenbosch MP (August 2021). "Targeting the Myeloid-Derived Suppressor Cell Compartment for Inducing Responsiveness to Immune Checkpoint Blockade Is Best Limited to Specific Subtypes of Gastric Cancers". Gastroenterology. 161 (2): 727. doi:10.1053/j.gastro.2021.03.047. PMID 33798523.
Kucerova P, Cervinkova M (April 2016). "Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment". Anti-Cancer Drugs. 27 (4): 269–77. doi:10.1097/CAD.0000000000000337. PMC 4777220. PMID 26813865.
Kienle GS (March 2012). "Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations". Global Advances in Health and Medicine. 1 (1): 92–100. doi:10.7453/gahmj.2012.1.1.016. PMC 3833486. PMID 24278806.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. (December 2014). "Classification of current anticancer immunotherapies". Oncotarget. 5 (24): 12472–12508. doi:10.18632/oncotarget.2998. PMC 4350348. PMID 25537519.
Riddell SR (July 2001). "Progress in cancer vaccines by enhanced self-presentation". Proceedings of the National Academy of Sciences of the United States of America. 98 (16): 8933–35. Bibcode:2001PNAS...98.8933R. doi:10.1073/pnas.171326398. PMC 55350. PMID 11481463.
Palucka K, Banchereau J (July 2013). "Dendritic-cell-based therapeutic cancer vaccines". Immunity. 39 (1): 38–48. doi:10.1016/j.immuni.2013.07.004. PMC 3788678. PMID 23890062.
Hirayama M, Nishimura Y (July 2016). "The present status and future prospects of peptide-based cancer vaccines". International Immunology. 28 (7): 319–28. doi:10.1093/intimm/dxw027. PMID 27235694.
Dastmalchi F, Karachi A, Mitchell D (June 2018). "Dendritic Cell Therapy". eLS. American Cancer Society. pp. 1–27. doi:10.1002/9780470015902.a0024243. ISBN 9780470015902. S2CID 155185753.
Gardner TA, Elzey BD, Hahn NM (April 2012). "Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer". Human Vaccines & Immunotherapeutics. 8 (4): 534–39. doi:10.4161/hv.19795. PMID 22832254.
Oudard S (May 2013). "Progress in emerging therapies for advanced prostate cancer". Cancer Treatment Reviews. 39 (3): 275–89. doi:10.1016/j.ctrv.2012.09.005. PMID 23107383.
Sims RB (June 2012). "Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate-resistant prostate cancer". Vaccine. 30 (29): 4394–97. doi:10.1016/j.vaccine.2011.11.058. PMID 22122856.
Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, et al. (January 2013). "Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer". Cancer Control. 20 (1): 7–16. doi:10.1177/107327481302000103. PMID 23302902.
Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". Nature Reviews. Immunology. 12 (4): 269–81. doi:10.1038/nri3191. PMC 6292222. PMID 22437939.
Barros MS, de Araújo ND, Magalhães-Gama F, Pereira Ribeiro TL, Alves Hanna FS, Tarragô AM, et al. (22 September 2021). "γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends". Frontiers in Immunology. 12: 729085. doi:10.3389/fimmu.2021.729085. PMC 8493128. PMID 34630403.
Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. (February 2014). "Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells". Journal of Translational Medicine. 12: 45. doi:10.1186/1479-5876-12-45. PMC 3926263. PMID 24528541.
Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS, et al. (March 2022). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. PMC 9376243. PMID 35332339.
Zhao L, Cao YJ (2019). "Engineered T Cell Therapy for Cancer in the Clinic". Frontiers in Immunology. 10: 2250. doi:10.3389/fimmu.2019.02250. PMC 6798078. PMID 31681259.
Yao S, Zhu Y, Chen L (February 2013). "Advances in targeting cell surface signalling molecules for immune modulation". Nature Reviews. Drug Discovery. 12 (2): 130–146. doi:10.1038/nrd3877. PMC 3698571. PMID 23370250.
Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
Harding FA, Stickler MM, Razo J, DuBridge RB (May–June 2010). "The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions". mAbs. 2 (3): 256–65. doi:10.4161/mabs.2.3.11641. PMC 2881252. PMID 20400861.
Gadd AJ, Greco F, Cobb AJ, Edwards AD (August 2015). "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity" (PDF). Bioconjugate Chemistry. 26 (8): 1743–52. doi:10.1021/acs.bioconjchem.5b00302. PMID 26133029. S2CID 26307107. We demonstrate here for the first time the successful conjugation of a small molecule TLR7 agonist to an antitumor mAb (the anti-hCD20 rituximab) without compromising antigen specificity.
Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. (August 2014). "Type I and type II Fc receptors regulate innate and adaptive immunity". Nature Immunology. 15 (8): 707–16. doi:10.1038/ni.2939. PMC 7430760. PMID 25045879.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. (June 2012). "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer". The New England Journal of Medicine. 366 (26): 2443–54. doi:10.1056/NEJMoa1200690. PMC 3544539. PMID 22658127.
Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (October 2015). "FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis". Cancer Cell. 28 (4): 543. doi:10.1016/j.ccell.2015.09.011. PMID 28854351.
Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. (May 2017). "In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy". Science Translational Medicine. 9 (389): eaal3604. doi:10.1126/scitranslmed.aal3604. PMC 5734617. PMID 28490665.
Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV (July 2016). "Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement". Cancer Cell. 29 (6): 820–31. doi:10.1016/j.ccell.2016.05.001. PMC 4975533. PMID 27265505.
Weiner LM, Surana R, Wang S (May 2010). "Monoclonal antibodies: versatile platforms for cancer immunotherapy". Nature Reviews. Immunology. 10 (5): 317–27. doi:10.1038/nri2744. PMC 3508064. PMID 20414205.
Seidel UJ, Schlegel P, Lang P (2013). "Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies". Frontiers in Immunology. 4: 76. doi:10.3389/fimmu.2013.00076. PMC 3608903. PMID 23543707.
Jaiswal S, Chao MP, Majeti R, Weissman IL (June 2010). "Macrophages as mediators of tumor immunosurveillance". Trends in Immunology. 31 (6): 212–19. doi:10.1016/j.it.2010.04.001. PMC 3646798. PMID 20452821.
Weiskopf K (May 2017). "Cancer immunotherapy targeting the CD47/SIRPα axis". European Journal of Cancer. 76: 100–09. doi:10.1016/j.ejca.2017.02.013. PMID 28286286.
Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (March 2017). "The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer". Immunological Reviews. 276 (1): 145–64. doi:10.1111/imr.12527. PMID 28258703. S2CID 6275163.
Veillette A, Chen J (March 2018). "SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy". Trends in Immunology. 39 (3): 173–84. doi:10.1016/j.it.2017.12.005. PMID 29336991.
Ahmed M, Cheung NK (January 2014). "Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy". FEBS Letters. 588 (2): 288–97. Bibcode:2014FEBSL.588..288A. doi:10.1016/j.febslet.2013.11.030. PMID 24295643.
Gelderman KA, Tomlinson S, Ross GD, Gorter A (March 2004). "Complement function in mAb-mediated cancer immunotherapy". Trends in Immunology. 25 (3): 158–64. doi:10.1016/j.it.2004.01.008. PMID 15036044.
Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.
Demko S, Summers J, Keegan P, Pazdur R (February 2008). "FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia". The Oncologist. 13 (2): 167–74. CiteSeerX 10.1.1.503.6960. doi:10.1634/theoncologist.2007-0218. PMID 18305062.
Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373. S2CID 4608450.
Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, et al. (September 2010). "U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab". Clinical Cancer Research. 16 (17): 4331–38. doi:10.1158/1078-0432.CCR-10-0570. PMID 20601446.
Byrd JC, Stilgenbauer S, Flinn IW (1 January 2004). "Chronic lymphocytic leukemia". Hematology. American Society of Hematology. Education Program. 2004 (1): 163–83. doi:10.1182/asheducation-2004.1.163. PMID 15561682.
Dearden C (July 2012). "How I treat prolymphocytic leukemia". Blood. 120 (3): 538–51. doi:10.1182/blood-2012-01-380139. PMID 22649104.
Madhusoodanan J (9 August 2023). "How a controversial US drug policy could be harming cancer patients worldwide". Nature. 620 (7973): 264–267. Bibcode:2023Natur.620..264M. doi:10.1038/d41586-023-02492-x. PMID 37558845. Retrieved 21 August 2023.
Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (June 2011). "Ipilimumab". Nature Reviews. Drug Discovery. 10 (6): 411–12. doi:10.1038/nrd3463. PMID 21629286.
Lipson EJ, Drake CG (November 2011). "Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma". Clinical Cancer Research. 17 (22): 6958–62. doi:10.1158/1078-0432.CCR-11-1595. PMC 3575079. PMID 21900389.
Chambers CA, Kuhns MS, Egen JG, Allison JP (2001). "CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy". Annual Review of Immunology. 19: 565–94. doi:10.1146/annurev.immunol.19.1.565. PMID 11244047.
Postow MA, Callahan MK, Wolchok JD (June 2015). "Immune Checkpoint Blockade in Cancer Therapy". Journal of Clinical Oncology. 33 (17): 1974–82. doi:10.1200/JCO.2014.59.4358. PMC 4980573. PMID 25605845.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017). "Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy". Frontiers in Pharmacology. 8: 49. doi:10.3389/fphar.2017.00049. PMC 5296331. PMID 28228726.
Castillo J, Perez K (2010). "The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies". Journal of Blood Medicine. 1: 1–8. doi:10.2147/jbm.s7284. PMC 3262337. PMID 22282677.
Zhang B (July–August 2009). "Ofatumumab". mAbs. 1 (4): 326–31. doi:10.4161/mabs.1.4.8895. PMC 2726602. PMID 20068404.
Keating GM (July 2010). "Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma". Drugs. 70 (11): 1445–76. doi:10.2165/11201110-000000000-00000. PMID 20614951.
Plosker GL, Figgitt DP (2003). "Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia". Drugs. 63 (8): 803–43. doi:10.2165/00003495-200363080-00005. PMID 12662126.
Cerny T, Borisch B, Introna M, Johnson P, Rose AL (November 2002). "Mechanism of action of rituximab". Anti-Cancer Drugs. 13 (Suppl 2): S3–10. doi:10.1097/00001813-200211002-00002. PMID 12710585. S2CID 25061294.
Weiner GJ (April 2010). "Rituximab: mechanism of action". Seminars in Hematology. 47 (2): 115–23. doi:10.1053/j.seminhematol.2010.01.011. PMC 2848172. PMID 20350658.
Ganesan S, Mehnert J (9 March 2020). "Biomarkers for Response to Immune Checkpoint Blockade". Annual Review of Cancer Biology. 4 (1): 331–351. doi:10.1146/annurev-cancerbio-030419-033604.
Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian Y, et al. (October 2023). "Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors". J Immunother Cancer. 11 (10): e007699. doi:10.1136/jitc-2023-007699. PMC 10619027. PMID 37899129.
Yu B, Peppelenbosch M, Fuhler G (January 2024). "Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors". J Immunother Cancer. 12 (1): e008422. doi:10.1136/jitc-2023-008422. PMC 10806497. PMID 38242721.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. (2017). "Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer". ESMO Open. 2 (2): e000213. doi:10.1136/esmoopen-2017-000213. PMC 5518304. PMID 28761757.
Cameron F, Whiteside G, Perry C (May 2011). "Ipilimumab: first global approval". Drugs. 71 (8): 1093–104. doi:10.2165/11594010-000000000-00000. PMID 21668044.
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. (June 2012). "Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study". Journal of Clinical Oncology. 30 (17): 2046–54. doi:10.1200/JCO.2011.38.4032. PMID 22547592.
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. (September 2013). "Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer". Journal of Immunotherapy. 36 (7): 382–89. doi:10.1097/CJI.0b013e31829fb7a2. PMC 3779664. PMID 23924790.
Gougis P, Hamy AS, Jochum F, Bihan K, Carbonnel M, Salem JE, et al. (April 2024). "Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns". JAMA Network Open. 7 (4): e245625. doi:10.1001/jamanetworkopen.2024.5625. PMC 11024778. PMID 38630478.
van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, et al. (February 2017). "Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer". European Journal of Immunology. 47 (2): 385–93. doi:10.1002/eji.201646583. PMID 27873300. S2CID 2463514.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. (November 2015). "Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–2113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, et al. (March 2018). "The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8⁺ T cells". Scientific Reports. 8 (1): 5336. Bibcode:2018NatSR...8.5336G. doi:10.1038/s41598-018-23549-2. PMC 5871872. PMID 29593227.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. (November 2015). "Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–2113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, et al. (25 September 2020). "Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade". bioRxiv 10.1101/2020.09.24.306571.
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. (February 2016). "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". Immunity. 44 (2): 343–54. doi:10.1016/j.immuni.2015.11.024. PMC 4758865. PMID 26872698.
Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD (2017). "Combination immunotherapy: a road map". Journal for Immunotherapy of Cancer. 5: 16. doi:10.1186/s40425-017-0218-5. PMC 5319100. PMID 28239469.
Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–84. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
Mehta A, Oklu R, Sheth RA (2015). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". Gastroenterology Research and Practice. 2016: 9251375. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
Tang J, Shalabi A, Hubbard-Lucey VM (January 2018). "Comprehensive analysis of the clinical immuno-oncology landscape". Annals of Oncology. 29 (1): 84–91. doi:10.1093/annonc/mdx755. PMID 29228097.
Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, et al. (March 2018). "Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity". The Journal of Experimental Medicine. 215 (3): 877–93. doi:10.1084/jem.20171435. PMC 5839759. PMID 29436395.
Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. (21 May 2018). "TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy". Nature Biomedical Engineering. 2 (8): 578–588. doi:10.1038/s41551-018-0236-8. PMC 6192054. PMID 31015631.
Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. (June 2024). "JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma". Science. 384 (6702): eade8520. doi:10.1126/science.ade8520. PMC 11283877. PMID 38900864.
Dranoff G (January 2004). "Cytokines in cancer pathogenesis and cancer therapy". Nature Reviews. Cancer. 4 (1): 11–22. doi:10.1038/nrc1252. PMID 14708024. S2CID 42092046.
Dunn GP, Koebel CM, Schreiber RD (November 2006). "Interferons, immunity and cancer immunoediting". Nature Reviews. Immunology. 6 (11): 836–48. doi:10.1038/nri1961. PMID 17063185. S2CID 223082.
Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). "Interferon lambda: a new sword in cancer immunotherapy". Clinical & Developmental Immunology. 2011: 349575. doi:10.1155/2011/349575. PMC 3235441. PMID 22190970.
Razaghi A, Owens L, Heimann K (December 2016). "Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation". Journal of Biotechnology. 240: 48–60. doi:10.1016/j.jbiotec.2016.10.022. PMID 27794496.
Coventry BJ, Ashdown ML (2012). "The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses". Cancer Management and Research. 4: 215–21. doi:10.2147/cmar.s33979. PMC 3421468. PMID 22904643.
Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, et al. (February 2018). "PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics". Diagnostic Pathology. 13 (1): 12. doi:10.1186/s13000-018-0689-9. PMC 5807740. PMID 29426340.
Dacic S (April 2018). "Time is up for PD-L1 testing standardization in lung cancer". Annals of Oncology. 29 (4): 791–792. doi:10.1093/annonc/mdy069. PMID 29688334.
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. (November 2017). "Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers". Molecular Cancer Therapeutics. 16 (11): 2598–2608. doi:10.1158/1535-7163.MCT-17-0386. PMC 5670009. PMID 28835386.
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. (December 2019). "Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma". Nature Medicine. 25 (12): 1916–1927. doi:10.1038/s41591-019-0654-5. PMC 6898788. PMID 31792460.
Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. (September 2020). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial". Nature Medicine. 26 (11): 1733–1741. doi:10.1038/s41591-020-1044-8. PMC 8493486. PMID 32895571.
Fukuhara H, Ino Y, Todo T (October 2016). "Oncolytic virus therapy: A new era of cancer treatment at dawn". Cancer Science. 107 (10): 1373–79. doi:10.1111/cas.13027. PMC 5084676. PMID 27486853.
Haddad D (2017). "Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery". Frontiers in Oncology. 7: 96. doi:10.3389/fonc.2017.00096. PMC 5440573. PMID 28589082.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (January 2018). "Cancer immunotherapy beyond immune checkpoint inhibitors". Journal of Hematology & Oncology. 11 (1): 8. doi:10.1186/s13045-017-0552-6. PMC 5767051. PMID 29329556.
Lawler SE, Speranza MC, Cho CF, Chiocca EA (June 2017). "Oncolytic Viruses in Cancer Treatment: A Review". JAMA Oncology. 3 (6): 841–849. doi:10.1001/jamaoncol.2016.2064. PMID 27441411. S2CID 39321536.
Aleem E (June 2013). "β-Glucans and their applications in cancer therapy: focus on human studies". Anti-Cancer Agents in Medicinal Chemistry. 13 (5): 709–19. doi:10.2174/1871520611313050007. PMID 23293888.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. (December 2014). "Genetic basis for clinical response to CTLA-4 blockade in melanoma". The New England Journal of Medicine. 371 (23): 2189–99. doi:10.1056/NEJMoa1406498. PMC 4315319. PMID 25409260.
Schumacher TN, Schreiber RD (April 2015). "Neoantigens in cancer immunotherapy". Science. 348 (6230): 69–74. Bibcode:2015Sci...348...69S. doi:10.1126/science.aaa4971. PMID 25838375.

drugs.com

"Opdivo (nivolumab) FDA Approval History". Drugs.com.
"Trastuzumab - Drugs.com". www.drugs.com. Archived from the original on 7 April 2017. Retrieved 21 December 2016.
"Trastuzumab Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 3 December 2019. Retrieved 3 December 2019.
"Trastuzumab". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.

europa.eu

ema.europa.eu

"Tecentriq EPAR". European Medicines Agency. 29 September 2017. Retrieved 31 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer" (PDF). European Medicines Agency. 9 January 2017. Archived from the original (PDF) on 5 August 2017. Retrieved 29 April 2017.
"Bavencio: EPAR - Product Information" (PDF). European Medicines Agency. 18 September 2017. Archived from the original (PDF) on 17 June 2018. Retrieved 23 February 2018.
"Herzuma EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 November 2020. Retrieved 28 July 2020.
"Herwenda EPAR". European Medicines Agency. 15 November 2023. Archived from the original on 3 December 2023. Retrieved 11 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Kanjinti EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 31 October 2020. Retrieved 28 July 2020.
"Ontruzant EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2020. Retrieved 28 July 2020.
"Tuznue EPAR". European Medicines Agency. 26 July 2024. Retrieved 29 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Zercepac EPAR". European Medicines Agency (EMA). 26 May 2020. Archived from the original on 28 July 2020. Retrieved 28 July 2020.
"Ogivri EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 March 2020. Retrieved 28 July 2020.
"Herceptin EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 28 July 2020. Retrieved 28 July 2020.

ec.europa.eu

"Herzuma PI". Union Register of medicinal products. 13 February 2018. Retrieved 30 September 2024.
"Herwenda Product information". Union Register of medicinal products. 16 November 2023. Archived from the original on 26 November 2023. Retrieved 11 December 2023.
"Kanjinti PI". Union Register of medicinal products. 18 May 2018. Retrieved 30 September 2024.
"Ontruzant PI". Union Register of medicinal products. 17 November 2017. Retrieved 30 September 2024.
"Tuznue PI". Union Register of medicinal products. 24 September 2024. Retrieved 27 September 2024.
"Zercepac PI". Union Register of medicinal products. 28 July 2020. Retrieved 30 September 2024.
"Ogivri PI". Union Register of medicinal products. 14 December 2018. Retrieved 30 September 2024.

fda.gov

Office of the Commissioner. "Press Announcements – FDA approval brings first gene therapy to the United States". fda.gov. Retrieved 13 December 2017.
"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma". fda.gov. 18 October 2017. Retrieved 8 November 2017.
"FDA approves new, targeted treatment for bladder cancer". FDA. 18 May 2016. Retrieved 20 May 2016.
"FDA approves atezolizumab and hyaluronidase-tqjs". U.S. Food and Drug Administration. 12 September 2024. Archived from the original on 14 September 2024. Retrieved 14 September 2024. This article incorporates text from this source, which is in the public domain.}
Center for Drug Evaluation and Research. "Approved Drugs – Durvalumab (Imfinzi)". fda.gov. Retrieved 6 May 2017.
"FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC". FDA. 9 February 2019.
"FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC". FDA. 20 December 2019.
"Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma". FDA. 9 February 2019.
"FDA approves pembrolizumab for Merkel cell carcinoma". FDA. 20 December 2019.
"FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL". FDA. 9 February 2019.
"FDA grants approval to atezolizumab for alveolar soft part sarcoma". U.S. Food and Drug Administration (FDA). 9 December 2022. Retrieved 20 December 2022.
"FDA approves new, targeted treatment for bladder cancer" (Press release). U.S. Food and Drug Administration (FDA). 18 May 2016. Retrieved 20 May 2016. This article incorporates text from this source, which is in the public domain.
"FDA approves atezolizumab and hyaluronidase-tqjs". U.S. Food and Drug Administration. 12 September 2024. Archived from the original on 14 September 2024. Retrieved 14 September 2024. This article incorporates text from this source, which is in the public domain.}
"FDA approves first treatment for rare form of skin cancer". U.S. Food and Drug Administration (FDA) (Press release). 23 March 2017. Retrieved 2 August 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC". FDA. 9 February 2019.
"FDA approves first biosimilar for the treatment of certain breast and stomach cancers". U.S. Food and Drug Administration (FDA) (Press release). 10 September 2019. Archived from the original on 15 December 2019. Retrieved 18 February 2020.
"Trastuzumab Product Approval Information - Licensing Action 9/25/98". U.S. Food and Drug Administration (FDA). 18 December 2015. Archived from the original on 28 January 2017. Retrieved 3 December 2019. This article incorporates text from this source, which is in the public domain.
"FDA approves Encorafenib and Binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations". U.S. Food and Drug Administration. 27 June 2018.

accessdata.fda.gov

"US Food and Drug Administration – Avelumab Prescribing Label" (PDF).
"Pembrolizumab label" (PDF). FDA. May 2017. linked from Index page at FDA website November 2016
"HIGHLIGHTS OF PRESCRIBING INFORMATION - KEYTRUDA (Pembrolizumab)" (PDF). fda.gov. June 2018. Retrieved 27 February 2019.
"Highlights of prescribing information" (PDF). www.accessdata.fda.gov.

forbes.com

Flam F (22 January 2015). "Duke U Cancer Fraud Scandal: A Cautionary Tale For Obama's Precision Medicine Push". Forbes. Retrieved 21 April 2024.

ft.com

markets.ft.com

"European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types – Company Announcement - FT.com". markets.ft.com. Retrieved 5 March 2024.

gene.com

"FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy". Genentech (Press release). 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024.
"FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy". Genentech (Press release). 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024.

globenewswire.com

BeiGene, Ltd. (2016). "BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting" (Press release). Globe Newswire.

guildlink.com.au

"Herceptin (trastuzumab) powder for injection". Roche Products Pty Limited. 7 May 2021. Archived from the original on 8 March 2023. Retrieved 8 January 2023.
"Trastuzumab". Roche Products Pty Limited. 7 April 2022. Archived from the original on 8 January 2023.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

harvard.edu

ui.adsabs.harvard.edu

Riddell SR (July 2001). "Progress in cancer vaccines by enhanced self-presentation". Proceedings of the National Academy of Sciences of the United States of America. 98 (16): 8933–35. Bibcode:2001PNAS...98.8933R. doi:10.1073/pnas.171326398. PMC 55350. PMID 11481463.
Ahmed M, Cheung NK (January 2014). "Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy". FEBS Letters. 588 (2): 288–97. Bibcode:2014FEBSL.588..288A. doi:10.1016/j.febslet.2013.11.030. PMID 24295643.
Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373. S2CID 4608450.
Madhusoodanan J (9 August 2023). "How a controversial US drug policy could be harming cancer patients worldwide". Nature. 620 (7973): 264–267. Bibcode:2023Natur.620..264M. doi:10.1038/d41586-023-02492-x. PMID 37558845. Retrieved 21 August 2023.
Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, et al. (March 2018). "The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8⁺ T cells". Scientific Reports. 8 (1): 5336. Bibcode:2018NatSR...8.5336G. doi:10.1038/s41598-018-23549-2. PMC 5871872. PMID 29593227.
Schumacher TN, Schreiber RD (April 2015). "Neoantigens in cancer immunotherapy". Science. 348 (6230): 69–74. Bibcode:2015Sci...348...69S. doi:10.1126/science.aaa4971. PMID 25838375.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Ontruzant". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.

ibiotherapy.com

"Immunotherapy For Cancer". Retrieved 12 May 2023.

immuno-oncologynews.com

"Genentech Presents Positive Results of Atezolizumab in Advanced Bladder Cancer". 2 October 2015.

medicines.org.uk

"Pembrolizumab label at eMC". UK Electronic Medicines Compendium. 27 January 2017. Archived from the original on 13 December 2017. Retrieved 4 October 2018.

medscimonit.com

Domagała A, Kurpisz M (2001). "CD52 antigen--a review". Medical Science Monitor. 7 (2): 325–31. PMID 11257744.

melanoma.org

A public discussion by cancer patients from 2011 on the melanoma.org website shows costs and claims.

merckgroup.com

Merck Group. "Immuno-oncology Avelumab".

nature.com

Madhusoodanan J (9 August 2023). "How a controversial US drug policy could be harming cancer patients worldwide". Nature. 620 (7973): 264–267. Bibcode:2023Natur.620..264M. doi:10.1038/d41586-023-02492-x. PMID 37558845. Retrieved 21 August 2023.

newatlas.com

Irving M (29 March 2022). "Implantable immunotherapy "factory" fights cancer faster, more effectively". New Atlas. Retrieved 29 March 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kodach LL, Peppelenbosch MP (August 2021). "Targeting the Myeloid-Derived Suppressor Cell Compartment for Inducing Responsiveness to Immune Checkpoint Blockade Is Best Limited to Specific Subtypes of Gastric Cancers". Gastroenterology. 161 (2): 727. doi:10.1053/j.gastro.2021.03.047. PMID 33798523.
Kucerova P, Cervinkova M (April 2016). "Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment". Anti-Cancer Drugs. 27 (4): 269–77. doi:10.1097/CAD.0000000000000337. PMC 4777220. PMID 26813865.
Kienle GS (March 2012). "Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations". Global Advances in Health and Medicine. 1 (1): 92–100. doi:10.7453/gahmj.2012.1.1.016. PMC 3833486. PMID 24278806.
McCarthy EF (2006). "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas". The Iowa Orthopaedic Journal. 26: 154–8. PMC 1888599. PMID 16789469.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. (December 2014). "Classification of current anticancer immunotherapies". Oncotarget. 5 (24): 12472–12508. doi:10.18632/oncotarget.2998. PMC 4350348. PMID 25537519.
Riddell SR (July 2001). "Progress in cancer vaccines by enhanced self-presentation". Proceedings of the National Academy of Sciences of the United States of America. 98 (16): 8933–35. Bibcode:2001PNAS...98.8933R. doi:10.1073/pnas.171326398. PMC 55350. PMID 11481463.
Palucka K, Banchereau J (July 2013). "Dendritic-cell-based therapeutic cancer vaccines". Immunity. 39 (1): 38–48. doi:10.1016/j.immuni.2013.07.004. PMC 3788678. PMID 23890062.
Hirayama M, Nishimura Y (July 2016). "The present status and future prospects of peptide-based cancer vaccines". International Immunology. 28 (7): 319–28. doi:10.1093/intimm/dxw027. PMID 27235694.
Gardner TA, Elzey BD, Hahn NM (April 2012). "Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer". Human Vaccines & Immunotherapeutics. 8 (4): 534–39. doi:10.4161/hv.19795. PMID 22832254.
Oudard S (May 2013). "Progress in emerging therapies for advanced prostate cancer". Cancer Treatment Reviews. 39 (3): 275–89. doi:10.1016/j.ctrv.2012.09.005. PMID 23107383.
Sims RB (June 2012). "Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate-resistant prostate cancer". Vaccine. 30 (29): 4394–97. doi:10.1016/j.vaccine.2011.11.058. PMID 22122856.
Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, et al. (January 2013). "Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer". Cancer Control. 20 (1): 7–16. doi:10.1177/107327481302000103. PMID 23302902.
Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". Nature Reviews. Immunology. 12 (4): 269–81. doi:10.1038/nri3191. PMC 6292222. PMID 22437939.
Barros MS, de Araújo ND, Magalhães-Gama F, Pereira Ribeiro TL, Alves Hanna FS, Tarragô AM, et al. (22 September 2021). "γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends". Frontiers in Immunology. 12: 729085. doi:10.3389/fimmu.2021.729085. PMC 8493128. PMID 34630403.
Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. (February 2014). "Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells". Journal of Translational Medicine. 12: 45. doi:10.1186/1479-5876-12-45. PMC 3926263. PMID 24528541.
Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS, et al. (March 2022). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. PMC 9376243. PMID 35332339.
Zhao L, Cao YJ (2019). "Engineered T Cell Therapy for Cancer in the Clinic". Frontiers in Immunology. 10: 2250. doi:10.3389/fimmu.2019.02250. PMC 6798078. PMID 31681259.
Yao S, Zhu Y, Chen L (February 2013). "Advances in targeting cell surface signalling molecules for immune modulation". Nature Reviews. Drug Discovery. 12 (2): 130–146. doi:10.1038/nrd3877. PMC 3698571. PMID 23370250.
Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
Harding FA, Stickler MM, Razo J, DuBridge RB (May–June 2010). "The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions". mAbs. 2 (3): 256–65. doi:10.4161/mabs.2.3.11641. PMC 2881252. PMID 20400861.
Gadd AJ, Greco F, Cobb AJ, Edwards AD (August 2015). "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity" (PDF). Bioconjugate Chemistry. 26 (8): 1743–52. doi:10.1021/acs.bioconjchem.5b00302. PMID 26133029. S2CID 26307107. We demonstrate here for the first time the successful conjugation of a small molecule TLR7 agonist to an antitumor mAb (the anti-hCD20 rituximab) without compromising antigen specificity.
Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. (August 2014). "Type I and type II Fc receptors regulate innate and adaptive immunity". Nature Immunology. 15 (8): 707–16. doi:10.1038/ni.2939. PMC 7430760. PMID 25045879.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. (June 2012). "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer". The New England Journal of Medicine. 366 (26): 2443–54. doi:10.1056/NEJMoa1200690. PMC 3544539. PMID 22658127.
Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (October 2015). "FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis". Cancer Cell. 28 (4): 543. doi:10.1016/j.ccell.2015.09.011. PMID 28854351.
Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. (May 2017). "In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy". Science Translational Medicine. 9 (389): eaal3604. doi:10.1126/scitranslmed.aal3604. PMC 5734617. PMID 28490665.
Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV (July 2016). "Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement". Cancer Cell. 29 (6): 820–31. doi:10.1016/j.ccell.2016.05.001. PMC 4975533. PMID 27265505.
Weiner LM, Surana R, Wang S (May 2010). "Monoclonal antibodies: versatile platforms for cancer immunotherapy". Nature Reviews. Immunology. 10 (5): 317–27. doi:10.1038/nri2744. PMC 3508064. PMID 20414205.
Seidel UJ, Schlegel P, Lang P (2013). "Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies". Frontiers in Immunology. 4: 76. doi:10.3389/fimmu.2013.00076. PMC 3608903. PMID 23543707.
Jaiswal S, Chao MP, Majeti R, Weissman IL (June 2010). "Macrophages as mediators of tumor immunosurveillance". Trends in Immunology. 31 (6): 212–19. doi:10.1016/j.it.2010.04.001. PMC 3646798. PMID 20452821.
Weiskopf K (May 2017). "Cancer immunotherapy targeting the CD47/SIRPα axis". European Journal of Cancer. 76: 100–09. doi:10.1016/j.ejca.2017.02.013. PMID 28286286.
Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (March 2017). "The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer". Immunological Reviews. 276 (1): 145–64. doi:10.1111/imr.12527. PMID 28258703. S2CID 6275163.
Veillette A, Chen J (March 2018). "SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy". Trends in Immunology. 39 (3): 173–84. doi:10.1016/j.it.2017.12.005. PMID 29336991.
Ahmed M, Cheung NK (January 2014). "Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy". FEBS Letters. 588 (2): 288–97. Bibcode:2014FEBSL.588..288A. doi:10.1016/j.febslet.2013.11.030. PMID 24295643.
Gelderman KA, Tomlinson S, Ross GD, Gorter A (March 2004). "Complement function in mAb-mediated cancer immunotherapy". Trends in Immunology. 25 (3): 158–64. doi:10.1016/j.it.2004.01.008. PMID 15036044.
Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.
Demko S, Summers J, Keegan P, Pazdur R (February 2008). "FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia". The Oncologist. 13 (2): 167–74. CiteSeerX 10.1.1.503.6960. doi:10.1634/theoncologist.2007-0218. PMID 18305062.
Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373. S2CID 4608450.
Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, et al. (September 2010). "U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab". Clinical Cancer Research. 16 (17): 4331–38. doi:10.1158/1078-0432.CCR-10-0570. PMID 20601446.
James JS, Dubs G (December 1997). "FDA approves new kind of lymphoma treatment. Food and Drug Administration". AIDS Treatment News (284): 2–3. PMID 11364912.
Byrd JC, Stilgenbauer S, Flinn IW (1 January 2004). "Chronic lymphocytic leukemia". Hematology. American Society of Hematology. Education Program. 2004 (1): 163–83. doi:10.1182/asheducation-2004.1.163. PMID 15561682.
Domagała A, Kurpisz M (2001). "CD52 antigen--a review". Medical Science Monitor. 7 (2): 325–31. PMID 11257744.
Dearden C (July 2012). "How I treat prolymphocytic leukemia". Blood. 120 (3): 538–51. doi:10.1182/blood-2012-01-380139. PMID 22649104.
Madhusoodanan J (9 August 2023). "How a controversial US drug policy could be harming cancer patients worldwide". Nature. 620 (7973): 264–267. Bibcode:2023Natur.620..264M. doi:10.1038/d41586-023-02492-x. PMID 37558845. Retrieved 21 August 2023.
Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (June 2011). "Ipilimumab". Nature Reviews. Drug Discovery. 10 (6): 411–12. doi:10.1038/nrd3463. PMID 21629286.
Lipson EJ, Drake CG (November 2011). "Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma". Clinical Cancer Research. 17 (22): 6958–62. doi:10.1158/1078-0432.CCR-11-1595. PMC 3575079. PMID 21900389.
Thumar JR, Kluger HM (December 2010). "Ipilimumab: a promising immunotherapy for melanoma". Oncology. 24 (14): 1280–88. PMID 21294471.
Chambers CA, Kuhns MS, Egen JG, Allison JP (2001). "CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy". Annual Review of Immunology. 19: 565–94. doi:10.1146/annurev.immunol.19.1.565. PMID 11244047.
Postow MA, Callahan MK, Wolchok JD (June 2015). "Immune Checkpoint Blockade in Cancer Therapy". Journal of Clinical Oncology. 33 (17): 1974–82. doi:10.1200/JCO.2014.59.4358. PMC 4980573. PMID 25605845.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017). "Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy". Frontiers in Pharmacology. 8: 49. doi:10.3389/fphar.2017.00049. PMC 5296331. PMID 28228726.
Castillo J, Perez K (2010). "The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies". Journal of Blood Medicine. 1: 1–8. doi:10.2147/jbm.s7284. PMC 3262337. PMID 22282677.
Zhang B (July–August 2009). "Ofatumumab". mAbs. 1 (4): 326–31. doi:10.4161/mabs.1.4.8895. PMC 2726602. PMID 20068404.
Keating GM (July 2010). "Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma". Drugs. 70 (11): 1445–76. doi:10.2165/11201110-000000000-00000. PMID 20614951.
Plosker GL, Figgitt DP (2003). "Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia". Drugs. 63 (8): 803–43. doi:10.2165/00003495-200363080-00005. PMID 12662126.
Cerny T, Borisch B, Introna M, Johnson P, Rose AL (November 2002). "Mechanism of action of rituximab". Anti-Cancer Drugs. 13 (Suppl 2): S3–10. doi:10.1097/00001813-200211002-00002. PMID 12710585. S2CID 25061294.
Weiner GJ (April 2010). "Rituximab: mechanism of action". Seminars in Hematology. 47 (2): 115–23. doi:10.1053/j.seminhematol.2010.01.011. PMC 2848172. PMID 20350658.
Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian Y, et al. (October 2023). "Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors". J Immunother Cancer. 11 (10): e007699. doi:10.1136/jitc-2023-007699. PMC 10619027. PMID 37899129.
Yu B, Peppelenbosch M, Fuhler G (January 2024). "Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors". J Immunother Cancer. 12 (1): e008422. doi:10.1136/jitc-2023-008422. PMC 10806497. PMID 38242721.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. (2017). "Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer". ESMO Open. 2 (2): e000213. doi:10.1136/esmoopen-2017-000213. PMC 5518304. PMID 28761757.
Cameron F, Whiteside G, Perry C (May 2011). "Ipilimumab: first global approval". Drugs. 71 (8): 1093–104. doi:10.2165/11594010-000000000-00000. PMID 21668044.
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. (June 2012). "Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study". Journal of Clinical Oncology. 30 (17): 2046–54. doi:10.1200/JCO.2011.38.4032. PMID 22547592.
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. (September 2013). "Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer". Journal of Immunotherapy. 36 (7): 382–89. doi:10.1097/CJI.0b013e31829fb7a2. PMC 3779664. PMID 23924790.
Gougis P, Hamy AS, Jochum F, Bihan K, Carbonnel M, Salem JE, et al. (April 2024). "Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns". JAMA Network Open. 7 (4): e245625. doi:10.1001/jamanetworkopen.2024.5625. PMC 11024778. PMID 38630478.
van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, et al. (February 2017). "Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer". European Journal of Immunology. 47 (2): 385–93. doi:10.1002/eji.201646583. PMID 27873300. S2CID 2463514.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. (November 2015). "Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–2113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, et al. (March 2018). "The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8⁺ T cells". Scientific Reports. 8 (1): 5336. Bibcode:2018NatSR...8.5336G. doi:10.1038/s41598-018-23549-2. PMC 5871872. PMID 29593227.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. (November 2015). "Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–2113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. (February 2016). "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". Immunity. 44 (2): 343–54. doi:10.1016/j.immuni.2015.11.024. PMC 4758865. PMID 26872698.
Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD (2017). "Combination immunotherapy: a road map". Journal for Immunotherapy of Cancer. 5: 16. doi:10.1186/s40425-017-0218-5. PMC 5319100. PMID 28239469.
Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–84. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
Mehta A, Oklu R, Sheth RA (2015). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". Gastroenterology Research and Practice. 2016: 9251375. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
Tang J, Shalabi A, Hubbard-Lucey VM (January 2018). "Comprehensive analysis of the clinical immuno-oncology landscape". Annals of Oncology. 29 (1): 84–91. doi:10.1093/annonc/mdx755. PMID 29228097.
Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, et al. (March 2018). "Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity". The Journal of Experimental Medicine. 215 (3): 877–93. doi:10.1084/jem.20171435. PMC 5839759. PMID 29436395.
Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. (21 May 2018). "TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy". Nature Biomedical Engineering. 2 (8): 578–588. doi:10.1038/s41551-018-0236-8. PMC 6192054. PMID 31015631.
Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. (June 2024). "JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma". Science. 384 (6702): eade8520. doi:10.1126/science.ade8520. PMC 11283877. PMID 38900864.
Dranoff G (January 2004). "Cytokines in cancer pathogenesis and cancer therapy". Nature Reviews. Cancer. 4 (1): 11–22. doi:10.1038/nrc1252. PMID 14708024. S2CID 42092046.
Dunn GP, Koebel CM, Schreiber RD (November 2006). "Interferons, immunity and cancer immunoediting". Nature Reviews. Immunology. 6 (11): 836–48. doi:10.1038/nri1961. PMID 17063185. S2CID 223082.
Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). "Interferon lambda: a new sword in cancer immunotherapy". Clinical & Developmental Immunology. 2011: 349575. doi:10.1155/2011/349575. PMC 3235441. PMID 22190970.
Razaghi A, Owens L, Heimann K (December 2016). "Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation". Journal of Biotechnology. 240: 48–60. doi:10.1016/j.jbiotec.2016.10.022. PMID 27794496.
Coventry BJ, Ashdown ML (2012). "The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses". Cancer Management and Research. 4: 215–21. doi:10.2147/cmar.s33979. PMC 3421468. PMID 22904643.
Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, et al. (February 2018). "PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics". Diagnostic Pathology. 13 (1): 12. doi:10.1186/s13000-018-0689-9. PMC 5807740. PMID 29426340.
Dacic S (April 2018). "Time is up for PD-L1 testing standardization in lung cancer". Annals of Oncology. 29 (4): 791–792. doi:10.1093/annonc/mdy069. PMID 29688334.
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. (November 2017). "Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers". Molecular Cancer Therapeutics. 16 (11): 2598–2608. doi:10.1158/1535-7163.MCT-17-0386. PMC 5670009. PMID 28835386.
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. (December 2019). "Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma". Nature Medicine. 25 (12): 1916–1927. doi:10.1038/s41591-019-0654-5. PMC 6898788. PMID 31792460.
Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. (September 2020). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial". Nature Medicine. 26 (11): 1733–1741. doi:10.1038/s41591-020-1044-8. PMC 8493486. PMID 32895571.
Fukuhara H, Ino Y, Todo T (October 2016). "Oncolytic virus therapy: A new era of cancer treatment at dawn". Cancer Science. 107 (10): 1373–79. doi:10.1111/cas.13027. PMC 5084676. PMID 27486853.
Haddad D (2017). "Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery". Frontiers in Oncology. 7: 96. doi:10.3389/fonc.2017.00096. PMC 5440573. PMID 28589082.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (January 2018). "Cancer immunotherapy beyond immune checkpoint inhibitors". Journal of Hematology & Oncology. 11 (1): 8. doi:10.1186/s13045-017-0552-6. PMC 5767051. PMID 29329556.
Lawler SE, Speranza MC, Cho CF, Chiocca EA (June 2017). "Oncolytic Viruses in Cancer Treatment: A Review". JAMA Oncology. 3 (6): 841–849. doi:10.1001/jamaoncol.2016.2064. PMID 27441411. S2CID 39321536.
Aleem E (June 2013). "β-Glucans and their applications in cancer therapy: focus on human studies". Anti-Cancer Agents in Medicinal Chemistry. 13 (5): 709–19. doi:10.2174/1871520611313050007. PMID 23293888.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. (December 2014). "Genetic basis for clinical response to CTLA-4 blockade in melanoma". The New England Journal of Medicine. 371 (23): 2189–99. doi:10.1056/NEJMoa1406498. PMC 4315319. PMID 25409260.
Schumacher TN, Schreiber RD (April 2015). "Neoantigens in cancer immunotherapy". Science. 348 (6230): 69–74. Bibcode:2015Sci...348...69S. doi:10.1126/science.aaa4971. PMID 25838375.

ncbi.nlm.nih.gov

Kucerova P, Cervinkova M (April 2016). "Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment". Anti-Cancer Drugs. 27 (4): 269–77. doi:10.1097/CAD.0000000000000337. PMC 4777220. PMID 26813865.
Kienle GS (March 2012). "Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations". Global Advances in Health and Medicine. 1 (1): 92–100. doi:10.7453/gahmj.2012.1.1.016. PMC 3833486. PMID 24278806.
McCarthy EF (2006). "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas". The Iowa Orthopaedic Journal. 26: 154–8. PMC 1888599. PMID 16789469.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. (December 2014). "Classification of current anticancer immunotherapies". Oncotarget. 5 (24): 12472–12508. doi:10.18632/oncotarget.2998. PMC 4350348. PMID 25537519.
Riddell SR (July 2001). "Progress in cancer vaccines by enhanced self-presentation". Proceedings of the National Academy of Sciences of the United States of America. 98 (16): 8933–35. Bibcode:2001PNAS...98.8933R. doi:10.1073/pnas.171326398. PMC 55350. PMID 11481463.
Palucka K, Banchereau J (July 2013). "Dendritic-cell-based therapeutic cancer vaccines". Immunity. 39 (1): 38–48. doi:10.1016/j.immuni.2013.07.004. PMC 3788678. PMID 23890062.
Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". Nature Reviews. Immunology. 12 (4): 269–81. doi:10.1038/nri3191. PMC 6292222. PMID 22437939.
Barros MS, de Araújo ND, Magalhães-Gama F, Pereira Ribeiro TL, Alves Hanna FS, Tarragô AM, et al. (22 September 2021). "γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends". Frontiers in Immunology. 12: 729085. doi:10.3389/fimmu.2021.729085. PMC 8493128. PMID 34630403.
Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. (February 2014). "Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells". Journal of Translational Medicine. 12: 45. doi:10.1186/1479-5876-12-45. PMC 3926263. PMID 24528541.
Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS, et al. (March 2022). "Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells". Nature Biotechnology. 40 (8): 1250–1258. doi:10.1038/s41587-022-01245-x. PMC 9376243. PMID 35332339.
Zhao L, Cao YJ (2019). "Engineered T Cell Therapy for Cancer in the Clinic". Frontiers in Immunology. 10: 2250. doi:10.3389/fimmu.2019.02250. PMC 6798078. PMID 31681259.
Yao S, Zhu Y, Chen L (February 2013). "Advances in targeting cell surface signalling molecules for immune modulation". Nature Reviews. Drug Discovery. 12 (2): 130–146. doi:10.1038/nrd3877. PMC 3698571. PMID 23370250.
Harding FA, Stickler MM, Razo J, DuBridge RB (May–June 2010). "The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions". mAbs. 2 (3): 256–65. doi:10.4161/mabs.2.3.11641. PMC 2881252. PMID 20400861.
Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. (August 2014). "Type I and type II Fc receptors regulate innate and adaptive immunity". Nature Immunology. 15 (8): 707–16. doi:10.1038/ni.2939. PMC 7430760. PMID 25045879.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. (June 2012). "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer". The New England Journal of Medicine. 366 (26): 2443–54. doi:10.1056/NEJMoa1200690. PMC 3544539. PMID 22658127.
Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. (May 2017). "In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy". Science Translational Medicine. 9 (389): eaal3604. doi:10.1126/scitranslmed.aal3604. PMC 5734617. PMID 28490665.
Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV (July 2016). "Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement". Cancer Cell. 29 (6): 820–31. doi:10.1016/j.ccell.2016.05.001. PMC 4975533. PMID 27265505.
Weiner LM, Surana R, Wang S (May 2010). "Monoclonal antibodies: versatile platforms for cancer immunotherapy". Nature Reviews. Immunology. 10 (5): 317–27. doi:10.1038/nri2744. PMC 3508064. PMID 20414205.
Seidel UJ, Schlegel P, Lang P (2013). "Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies". Frontiers in Immunology. 4: 76. doi:10.3389/fimmu.2013.00076. PMC 3608903. PMID 23543707.
Jaiswal S, Chao MP, Majeti R, Weissman IL (June 2010). "Macrophages as mediators of tumor immunosurveillance". Trends in Immunology. 31 (6): 212–19. doi:10.1016/j.it.2010.04.001. PMC 3646798. PMID 20452821.
Lipson EJ, Drake CG (November 2011). "Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma". Clinical Cancer Research. 17 (22): 6958–62. doi:10.1158/1078-0432.CCR-11-1595. PMC 3575079. PMID 21900389.
Postow MA, Callahan MK, Wolchok JD (June 2015). "Immune Checkpoint Blockade in Cancer Therapy". Journal of Clinical Oncology. 33 (17): 1974–82. doi:10.1200/JCO.2014.59.4358. PMC 4980573. PMID 25605845.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017). "Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy". Frontiers in Pharmacology. 8: 49. doi:10.3389/fphar.2017.00049. PMC 5296331. PMID 28228726.
Castillo J, Perez K (2010). "The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies". Journal of Blood Medicine. 1: 1–8. doi:10.2147/jbm.s7284. PMC 3262337. PMID 22282677.
Zhang B (July–August 2009). "Ofatumumab". mAbs. 1 (4): 326–31. doi:10.4161/mabs.1.4.8895. PMC 2726602. PMID 20068404.
Janeway C, Travers P, Walport M, Shlomchik M (2001). Immunobiology (Fifth ed.). New York and London: Garland Science. ISBN 978-0-8153-4101-7.^{[page needed]}
Weiner GJ (April 2010). "Rituximab: mechanism of action". Seminars in Hematology. 47 (2): 115–23. doi:10.1053/j.seminhematol.2010.01.011. PMC 2848172. PMID 20350658.
Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian Y, et al. (October 2023). "Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors". J Immunother Cancer. 11 (10): e007699. doi:10.1136/jitc-2023-007699. PMC 10619027. PMID 37899129.
Yu B, Peppelenbosch M, Fuhler G (January 2024). "Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors". J Immunother Cancer. 12 (1): e008422. doi:10.1136/jitc-2023-008422. PMC 10806497. PMID 38242721.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. (2017). "Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer". ESMO Open. 2 (2): e000213. doi:10.1136/esmoopen-2017-000213. PMC 5518304. PMID 28761757.
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. (September 2013). "Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer". Journal of Immunotherapy. 36 (7): 382–89. doi:10.1097/CJI.0b013e31829fb7a2. PMC 3779664. PMID 23924790.
Gougis P, Hamy AS, Jochum F, Bihan K, Carbonnel M, Salem JE, et al. (April 2024). "Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns". JAMA Network Open. 7 (4): e245625. doi:10.1001/jamanetworkopen.2024.5625. PMC 11024778. PMID 38630478.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. (November 2015). "Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–2113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, et al. (March 2018). "The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8⁺ T cells". Scientific Reports. 8 (1): 5336. Bibcode:2018NatSR...8.5336G. doi:10.1038/s41598-018-23549-2. PMC 5871872. PMID 29593227.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. (November 2015). "Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance". The Journal of Experimental Medicine. 212 (12): 2095–2113. doi:10.1084/jem.20150304. PMC 4647263. PMID 26527801.
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. (February 2016). "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". Immunity. 44 (2): 343–54. doi:10.1016/j.immuni.2015.11.024. PMC 4758865. PMID 26872698.
Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD (2017). "Combination immunotherapy: a road map". Journal for Immunotherapy of Cancer. 5: 16. doi:10.1186/s40425-017-0218-5. PMC 5319100. PMID 28239469.
Mehta A, Oklu R, Sheth RA (2015). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". Gastroenterology Research and Practice. 2016: 9251375. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, et al. (March 2018). "Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity". The Journal of Experimental Medicine. 215 (3): 877–93. doi:10.1084/jem.20171435. PMC 5839759. PMID 29436395.
Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. (21 May 2018). "TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy". Nature Biomedical Engineering. 2 (8): 578–588. doi:10.1038/s41551-018-0236-8. PMC 6192054. PMID 31015631.
Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). "Interferon lambda: a new sword in cancer immunotherapy". Clinical & Developmental Immunology. 2011: 349575. doi:10.1155/2011/349575. PMC 3235441. PMID 22190970.
Coventry BJ, Ashdown ML (2012). "The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses". Cancer Management and Research. 4: 215–21. doi:10.2147/cmar.s33979. PMC 3421468. PMID 22904643.
Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, et al. (February 2018). "PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics". Diagnostic Pathology. 13 (1): 12. doi:10.1186/s13000-018-0689-9. PMC 5807740. PMID 29426340.
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. (November 2017). "Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers". Molecular Cancer Therapeutics. 16 (11): 2598–2608. doi:10.1158/1535-7163.MCT-17-0386. PMC 5670009. PMID 28835386.
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. (December 2019). "Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma". Nature Medicine. 25 (12): 1916–1927. doi:10.1038/s41591-019-0654-5. PMC 6898788. PMID 31792460.
Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. (September 2020). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial". Nature Medicine. 26 (11): 1733–1741. doi:10.1038/s41591-020-1044-8. PMC 8493486. PMID 32895571.
Fukuhara H, Ino Y, Todo T (October 2016). "Oncolytic virus therapy: A new era of cancer treatment at dawn". Cancer Science. 107 (10): 1373–79. doi:10.1111/cas.13027. PMC 5084676. PMID 27486853.
Haddad D (2017). "Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery". Frontiers in Oncology. 7: 96. doi:10.3389/fonc.2017.00096. PMC 5440573. PMID 28589082.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (January 2018). "Cancer immunotherapy beyond immune checkpoint inhibitors". Journal of Hematology & Oncology. 11 (1): 8. doi:10.1186/s13045-017-0552-6. PMC 5767051. PMID 29329556.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. (December 2014). "Genetic basis for clinical response to CTLA-4 blockade in melanoma". The New England Journal of Medicine. 371 (23): 2189–99. doi:10.1056/NEJMoa1406498. PMC 4315319. PMID 25409260.

dailymed.nlm.nih.gov

"Rituxan Hycela- rituximab and hyaluronidase injection, solution". DailyMed. 8 July 2024. Retrieved 15 September 2024.
"Tecentriq- atezolizumab injection, solution". DailyMed. 3 June 2020. Retrieved 31 July 2020.
"Tecentriq Hybreza- atezolizumab and hyaluronidase-tqjs injection". DailyMed. 25 September 2024. Retrieved 5 October 2024.
"Bavencio- avelumab injection, solution, concentrate". DailyMed. 2 July 2020. Retrieved 2 August 2020.
"Kanjinti- trastuzumab-anns injection, powder, lyophilized, for solution; Kanjinti- trastuzumab-anns kit". DailyMed. 13 October 2022. Archived from the original on 5 December 2021. Retrieved 11 December 2023.
"Ogivri- trastuzumab kit; Ogivri- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 8 February 2021. Archived from the original on 7 December 2022. Retrieved 11 December 2023.
"Ontruzant- trastuzumab injection, powder, lyophilized, for solution; Ontruzant- ontruzant kit". DailyMed. 31 January 2023. Archived from the original on 13 August 2022. Retrieved 11 December 2023.
"Trazimera- trastuzumab-qyyp kit; Trazimera- trastuzumab-qyyp injection, powder, lyophilized, for solution". DailyMed. 14 February 2022. Archived from the original on 7 December 2022. Retrieved 11 December 2023.
"Herzuma- trastuzumab kit; Herzuma- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 6 February 2023. Archived from the original on 16 May 2021. Retrieved 11 December 2023.
"Ogivri- trastuzumab kit; Ogivri- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 28 July 2023. Archived from the original on 10 March 2024. Retrieved 11 December 2023.
"Herceptin- trastuzumab kit Herceptin- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 30 September 2019. Archived from the original on 4 August 2020. Retrieved 28 July 2020.

nobelprize.org

"The Nobel Prize in Physiology or Medicine 2018". NobelPrize.org. Retrieved 4 August 2019.

nytimes.com

Pollack A (18 May 2016). "F.D.A. Approves an Immunotherapy Drug for Bladder Cancer". The New York Times. ISSN 0362-4331. Retrieved 21 May 2016.

oncodaily.com

"Immunotherapy for Cancer: An Overview". Oncodaily.com. 29 May 2024. Retrieved 29 May 2024.

pfizer.com

Merck-Pfizer Alliance. "Merck-Pfizer Alliance Avelumab Fact Sheet" (PDF). Archived from the original (PDF) on 17 May 2017. Retrieved 2 December 2015.

pmlive.com

BMS gets two new cancer approvals in Europe. May 2016

prnewswire.com

"Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With Enhanze for Multiple Types of Cancer" (Press release). Halozyme Therapeutics. 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024 – via PR Newswire.
"Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With Enhanze for Multiple Types of Cancer" (Press release). Halozyme Therapeutics. 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024 – via PR Newswire.

psu.edu

citeseerx.ist.psu.edu

Demko S, Summers J, Keegan P, Pazdur R (February 2008). "FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia". The Oncologist. 13 (2): 167–74. CiteSeerX 10.1.1.503.6960. doi:10.1634/theoncologist.2007-0218. PMID 18305062.

reading.ac.uk

centaur.reading.ac.uk

Gadd AJ, Greco F, Cobb AJ, Edwards AD (August 2015). "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity" (PDF). Bioconjugate Chemistry. 26 (8): 1743–52. doi:10.1021/acs.bioconjchem.5b00302. PMID 26133029. S2CID 26307107. We demonstrate here for the first time the successful conjugation of a small molecule TLR7 agonist to an antitumor mAb (the anti-hCD20 rituximab) without compromising antigen specificity.

roche.com

Roche. "FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer".

sciencebasedmedicine.org

"Liquid biopsies" for cancer screening: Life-saving tests, or overdiagnosis and overtreatment taken to a new level? David Gorski, 28 September 2015, Science-Based Medicine website

semanticscholar.org

api.semanticscholar.org

Dastmalchi F, Karachi A, Mitchell D (June 2018). "Dendritic Cell Therapy". eLS. American Cancer Society. pp. 1–27. doi:10.1002/9780470015902.a0024243. ISBN 9780470015902. S2CID 155185753.
Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
Gadd AJ, Greco F, Cobb AJ, Edwards AD (August 2015). "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity" (PDF). Bioconjugate Chemistry. 26 (8): 1743–52. doi:10.1021/acs.bioconjchem.5b00302. PMID 26133029. S2CID 26307107. We demonstrate here for the first time the successful conjugation of a small molecule TLR7 agonist to an antitumor mAb (the anti-hCD20 rituximab) without compromising antigen specificity.
Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (March 2017). "The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer". Immunological Reviews. 276 (1): 145–64. doi:10.1111/imr.12527. PMID 28258703. S2CID 6275163.
Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.
Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373. S2CID 4608450.
Cerny T, Borisch B, Introna M, Johnson P, Rose AL (November 2002). "Mechanism of action of rituximab". Anti-Cancer Drugs. 13 (Suppl 2): S3–10. doi:10.1097/00001813-200211002-00002. PMID 12710585. S2CID 25061294.
van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, et al. (February 2017). "Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer". European Journal of Immunology. 47 (2): 385–93. doi:10.1002/eji.201646583. PMID 27873300. S2CID 2463514.
Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–84. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
Dranoff G (January 2004). "Cytokines in cancer pathogenesis and cancer therapy". Nature Reviews. Cancer. 4 (1): 11–22. doi:10.1038/nrc1252. PMID 14708024. S2CID 42092046.
Dunn GP, Koebel CM, Schreiber RD (November 2006). "Interferons, immunity and cancer immunoediting". Nature Reviews. Immunology. 6 (11): 836–48. doi:10.1038/nri1961. PMID 17063185. S2CID 223082.
Lawler SE, Speranza MC, Cho CF, Chiocca EA (June 2017). "Oncolytic Viruses in Cancer Treatment: A Review". JAMA Oncology. 3 (6): 841–849. doi:10.1001/jamaoncol.2016.2064. PMID 27441411. S2CID 39321536.

simbiosys.com

Biancalana M (14 December 2022). "Harnessing the immune system to develop breakthrough cancer therapies". Archived from the original on 4 December 2023. Retrieved 19 April 2024.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
"Trastucip and Tuzucip APMDS". Therapeutic Goods Administration (TGA). 29 July 2022. Archived from the original on 30 July 2022. Retrieved 2 August 2022.

washingtonpost.com

"Commencement speakers praise, advise local graduates . . ". Washington Post. ISSN 0190-8286. Retrieved 9 July 2021.

web.archive.org

Biancalana M (14 December 2022). "Harnessing the immune system to develop breakthrough cancer therapies". Archived from the original on 4 December 2023. Retrieved 19 April 2024.
"FDA approves atezolizumab and hyaluronidase-tqjs". U.S. Food and Drug Administration. 12 September 2024. Archived from the original on 14 September 2024. Retrieved 14 September 2024. This article incorporates text from this source, which is in the public domain.}
"FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy". Genentech (Press release). 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024.
"Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With Enhanze for Multiple Types of Cancer" (Press release). Halozyme Therapeutics. 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024 – via PR Newswire.
Pazdur R. "FDA approval for Ipilimumab". Archived from the original on 6 April 2015. Retrieved 7 November 2013.
"FDA approves atezolizumab and hyaluronidase-tqjs". U.S. Food and Drug Administration. 12 September 2024. Archived from the original on 14 September 2024. Retrieved 14 September 2024. This article incorporates text from this source, which is in the public domain.}
"FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy". Genentech (Press release). 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024.
"Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With Enhanze for Multiple Types of Cancer" (Press release). Halozyme Therapeutics. 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024 – via PR Newswire.
"Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer" (PDF). European Medicines Agency. 9 January 2017. Archived from the original (PDF) on 5 August 2017. Retrieved 29 April 2017.
"Bavencio: EPAR - Product Information" (PDF). European Medicines Agency. 18 September 2017. Archived from the original (PDF) on 17 June 2018. Retrieved 23 February 2018.
Merck-Pfizer Alliance. "Merck-Pfizer Alliance Avelumab Fact Sheet" (PDF). Archived from the original (PDF) on 17 May 2017. Retrieved 2 December 2015.
"Elotuzumab Package Insert" (PDF). Archived (PDF) from the original on 8 December 2015.
"Empliciti (elotuzumab) for Injection, for Intravenous Use. Full Prescribing Information" (PDF). Empliciti (elotuzumab) for US Healthcare Professionals. Princeton, New Jersey: Bristol-Myers Squibb Company. Archived from the original (PDF) on 8 December 2015.
"Pembrolizumab label at eMC". UK Electronic Medicines Compendium. 27 January 2017. Archived from the original on 13 December 2017. Retrieved 4 October 2018.
"Trastuzumab - Drugs.com". www.drugs.com. Archived from the original on 7 April 2017. Retrieved 21 December 2016.
"Kanjinti- trastuzumab-anns injection, powder, lyophilized, for solution; Kanjinti- trastuzumab-anns kit". DailyMed. 13 October 2022. Archived from the original on 5 December 2021. Retrieved 11 December 2023.
"Ogivri- trastuzumab kit; Ogivri- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 8 February 2021. Archived from the original on 7 December 2022. Retrieved 11 December 2023.
"Ontruzant- trastuzumab injection, powder, lyophilized, for solution; Ontruzant- ontruzant kit". DailyMed. 31 January 2023. Archived from the original on 13 August 2022. Retrieved 11 December 2023.
"Trazimera- trastuzumab-qyyp kit; Trazimera- trastuzumab-qyyp injection, powder, lyophilized, for solution". DailyMed. 14 February 2022. Archived from the original on 7 December 2022. Retrieved 11 December 2023.
"Herzuma- trastuzumab kit; Herzuma- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 6 February 2023. Archived from the original on 16 May 2021. Retrieved 11 December 2023.
"Herzuma EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 November 2020. Retrieved 28 July 2020.
"Herwenda EPAR". European Medicines Agency. 15 November 2023. Archived from the original on 3 December 2023. Retrieved 11 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Herwenda Product information". Union Register of medicinal products. 16 November 2023. Archived from the original on 26 November 2023. Retrieved 11 December 2023.
"Kanjinti EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 31 October 2020. Retrieved 28 July 2020.
"Ogivri- trastuzumab kit; Ogivri- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 28 July 2023. Archived from the original on 10 March 2024. Retrieved 11 December 2023.
"Ontruzant EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2020. Retrieved 28 July 2020.
"Trastucip and Tuzucip APMDS". Therapeutic Goods Administration (TGA). 29 July 2022. Archived from the original on 30 July 2022. Retrieved 2 August 2022.
"Zercepac EPAR". European Medicines Agency (EMA). 26 May 2020. Archived from the original on 28 July 2020. Retrieved 28 July 2020.
"Trastuzumab Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 3 December 2019. Retrieved 3 December 2019.
"Herceptin (trastuzumab) powder for injection". Roche Products Pty Limited. 7 May 2021. Archived from the original on 8 March 2023. Retrieved 8 January 2023.
"Trastuzumab". Roche Products Pty Limited. 7 April 2022. Archived from the original on 8 January 2023.
"Summary Basis of Decision - Ontruzant". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.
"Herceptin- trastuzumab kit Herceptin- trastuzumab injection, powder, lyophilized, for solution". DailyMed. 30 September 2019. Archived from the original on 4 August 2020. Retrieved 28 July 2020.
"Ogivri EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 March 2020. Retrieved 28 July 2020.
"Trastuzumab". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
"FDA approves first biosimilar for the treatment of certain breast and stomach cancers". U.S. Food and Drug Administration (FDA) (Press release). 10 September 2019. Archived from the original on 15 December 2019. Retrieved 18 February 2020.
"Herceptin EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 28 July 2020. Retrieved 28 July 2020.
"Trastuzumab Product Approval Information - Licensing Action 9/25/98". U.S. Food and Drug Administration (FDA). 18 December 2015. Archived from the original on 28 January 2017. Retrieved 3 December 2019. This article incorporates text from this source, which is in the public domain.
Avacta Life Sciences. "Affimer biotherapeutics target cancer's off-switch with PD-L1 inhibitor". Archived from the original on 6 August 2016. Retrieved 16 May 2016.
"Coriolus Versicolor". American Cancer Society. Archived from the original on 15 February 2006.

worldcat.org

search.worldcat.org

"Commencement speakers praise, advise local graduates . . ". Washington Post. ISSN 0190-8286. Retrieved 9 July 2021.
Pollack A (18 May 2016). "F.D.A. Approves an Immunotherapy Drug for Bladder Cancer". The New York Times. ISSN 0362-4331. Retrieved 21 May 2016.
Steele A (5 August 2016). "Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study". The Wall Street Journal. ISSN 0099-9660. Retrieved 5 August 2016.

wsj.com

Steele A (5 August 2016). "Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study". The Wall Street Journal. ISSN 0099-9660. Retrieved 5 August 2016.

zenodo.org

Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.